Discover 5+% Yielding Bargains That Outperform Bristol-Myers Squibb As A Buy

🌥️Trending News

BRISTOL-MYERS ($NYSE:BMY): Bristol-Myers Squibb is a leading biopharmaceutical company with a portfolio of innovative medicines, including oncology treatments, cardiovascular drugs, and HIV/AIDS medications. The company’s stock has seen strong performance in the past few years, making it an attractive purchase for investors.

However, there are even more compelling investments out there that offer yields of 5% or more while still outperforming Bristol-Myers Squibb as a buy. Investors who are looking for a more lucrative return on their money can find great opportunities in the market today. These investments with yields of 5% or more provide investors with an attractive return on their investment and the potential to increase their capital faster than Bristol-Myers Squibb. Whether it’s dividend stocks, real estate funds, or high-yield bonds, these investments come with the potential to generate more income than Bristol-Myers Squibb and provide greater returns over time. With the right research and analysis, investors can find a variety of investments that offer yields of 5% or more while outperforming Bristol-Myers Squibb as a buy. For those looking to diversify their portfolios and maximize their returns without having to invest heavily in one particular company or stock, these high-yield investments are a great option. With the potential for higher returns and lower risks than Bristol-Myers Squibb, these investments are an attractive option for any investor looking to make the most of their money.

Analysis

As a GoodWhale user, I recently completed an analysis of BRISTOL-MYERS SQUIBB‘s financials. According to the Star Chart, BRISTOL-MYERS SQUIBB is strong in dividend, growth, profitability and weak in asset. Moreover, the health score of BRISTOL-MYERS SQUIBB is 8/10, which indicates that the company is capable to sustain future operations in times of crisis. The analysis further classified BRISTOL-MYERS SQUIBB as a ‘rhino’ company, indicating that it has achieved moderate revenue or earnings growth. Given these factors, it is likely that investors such as long-term dividend investors or growth investors may be interested in such a company. More…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Bristol-myers Squibb. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Bristol-myers Squibb. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Bristol-myers Squibb. More…

Key Ratios Snapshot

Some of the financial key ratios for Bristol-myers Squibb are shown below. More…

Peers

The company was founded in 1887 and is headquartered in New York City. The company’s products are sold in over 100 countries. Bristol-Myers Squibb Co’s competitors include Merck & Co Inc, Amgen Inc, Eli Lilly and Co.

– Merck & Co Inc ($NYSE:MRK)

Merck & Co Inc is a global health care company that offers a wide range of products and services to customers in more than 140 countries. The company has a market cap of 236.25B as of 2022 and a Return on Equity of 28.84%. Merck & Co Inc is a diversified company that operates in four main business segments: Pharmaceuticals, Vaccines, Animal Health, and Consumer Care. The company’s products include prescription and over-the-counter medicines, vaccines, biologic therapies, and consumer and animal health products. Merck & Co Inc is one of the world’s largest pharmaceutical companies and is a leading provider of health care products and services.

– Amgen Inc ($NASDAQ:AMGN)

Amgen Inc is a large biotechnology company with a market cap of 132.76B as of 2022. The company has a strong return on equity of 460.37%. The company focuses on developing and delivering therapies for serious illnesses.

– Eli Lilly and Co ($NYSE:LLY)

Eli Lilly and Co is a pharmaceutical company with a market cap of 312.88B as of 2022. Its return on equity is 45.88%. The company focuses on the discovery, development, manufacture, and sale of pharmaceutical products. It offers products in the areas of endocrinology, diabetes, oncology, immunology, neuroscience, and erectile dysfunction.

Summary

Bristol-Myers Squibb is a great investment for those looking for a dependable stock with potential upside. The company has a strong track record of consistent dividend payouts, and its current dividend yield stands at an impressive 5%. In addition, the company has a strong balance sheet and good cash flow. Recent analyst reports suggest that the stock may be undervalued by the market, and could offer investors an excellent return if held for the long term.